Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
Pharmaniaga's financials are still messy with that massive PN17 hit, and until their balance sheet clears up, the fundamentals remain very shaky for long-term holding. 18-19 cents is just a psychological resistance; until they actually show sustainable profit growth, better to wait on the sidelines.
Pharma is very potential stock base on 2 important reasons:- 1.Production of human insulin contracts at its Puchong plant is scaling up. This moves the company away from being just a low-margin logistical middleman to a high-margin manufacturer. 2.Analysts estimate that Pharmaniaga could pay out 50% to 70% of its net profit as dividends. This is a major catalyst that will draw back large institutional funds.
Pharma will need to continuously show positive and strong Quarterly result & dividend to prove that the comeback is strong. This should not be difficult as it has strong Malaysian hospital customer base.
